Cerulean Pharma Inc. (NASDAQ:CERU)’s share price was up 6.5% during mid-day trading on Friday . The company traded as high as $2.97 and last traded at $2.93, with a volume of 116,950 shares. The stock had previously closed at $2.75.

A number of equities analysts have recently issued reports on CERU shares. Canaccord Genuity restated a “buy” rating and set a $15.00 price objective on shares of Cerulean Pharma in a research report on Wednesday, April 20th. Wedbush restated an “outperform” rating and set a $9.00 price objective on shares of Cerulean Pharma in a research report on Tuesday, April 19th. Leerink Swann restated a “buy” rating on shares of Cerulean Pharma in a research report on Sunday, June 26th. Finally, Janney Montgomery Scott started coverage on Cerulean Pharma in a research report on Wednesday, June 1st. They set a “buy” rating for the company. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Cerulean Pharma currently has a consensus rating of “Buy” and an average target price of $9.28.

The firm’s market capitalization is $79.08 million. The company has a 50 day moving average of $2.33 and a 200-day moving average of $2.49.

Cerulean Pharma (NASDAQ:CERU) last posted its earnings results on Monday, May 2nd. The company reported ($0.49) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.06. Equities analysts forecast that Cerulean Pharma Inc. will post ($1.80) EPS for the current fiscal year.

Cerulean Pharma Inc is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.